Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5652W HIGH $11.97
Volume
4.51 K
Value Traded
12.13 K
Short % Float
0.03%
+3.83%Week
-7.51%1 Month
-43.63%3 Month
-51.23%6 Month
-96.52%5 Year
-97.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.86 M
EPS (TTM)
-9.10
P/E Ratio
-
Ent. Value
4.86 M
Total Shares
1.82 M
Float Shares
1.06 M
Insiders
0.03%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ADXN Catalyst Timeline
Dated clinical, regulatory and corporate events for Addex Therapeutics Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Addex Therapeutics Ltd
651Total events
3Upcoming
140Tier-1 (high impact)
2007 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
●PK PD DataNTX-253Clinical Data
Phase 1 study provided pharmacokinetic data including food-effect and CSF assessments
schizophreniasource ↗
▲Safety Data UpdateNTX-253Clinical Data
Phase 1 study provided important safety and pharmacokinetic data for NTX-253
schizophreniasource ↗
▲Trial CompletionNTX-253Trial
Neurosterix completes Phase 1 clinical studies of NTX-253
schizophreniasource ↗
●Management ChangeCorporate
Jean-Philippe Rocher appointed Head of Pharmaceutical Development and member of Executive Management
▼Equity OfferingCorporate
Sold 52,970,533 shares for gross proceeds of CHF 2.3 million (USD 2.8 million)
▼Equity OfferingCorporate
Sold 52,970,533 shares for total gross proceeds of CHF 2.3 million (USD 2.8 million)
◆Trial CompletionNTX-253Trial
Phase 1 study with NTX-253 expected to complete in July
schizophreniasource ↗
▲Preclinical PoCPreclinical
GABAB PAM candidate demonstrates antitussive activity in bleomycin IPF chronic cough model
IPF-related chronic coughsource ↗
▲Preclinical PoCPreclinical
GABAB PAM demonstrates robust anti-tussive activity in NHP chronic cough model
chronic coughsource ↗
◆Trial CompletionNTX-253Trial
Phase 1 study of NTX-253 on track to complete in Q2 2026
schizophreniasource ↗
▼Equity OfferingCorporate
Raised USD 2.8 million through ATM offering agreement with H.C. Wainwright & Co
▲PublicationPresentation
Publication of preclinical data on mGlu7 NAM ADX71743 in Molecular Psychiatry
anxiety and fear-related disorders (PTSD)source ↗
▲First Patient DosedNTX-253Trial
First patient dosed in Phase 1 study of NTX-253
schizophreniasource ↗
▼Equity OfferingCorporate
Issuance of 34,300,000 new registered shares to create treasury shares
◆Quarterly UpdateCorporate
Host conference call to discuss financial results and provide business update
▲Preclinical PoCPreclinical
GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models
chronic coughsource ↗
▲IND Enabling CompletePreclinical
Indivior advanced GABAB PAM program through IND enabling studies
substance use disorderssource ↗
▲Partnership / LicenseCorporate
Entered option agreement with Sinntaxis for exclusive license to IP covering mGlu5 NAM in brain injury recovery
brain injury recoverysource ↗
▲Poster PresentationPresentation
Preclinical GABAB PAM chronic cough data presented at 10th American Cough Conference
chronic coughsource ↗
▲Preclinical PoCPreclinical
Robust anti-tussive activity demonstrated in multiple preclinical models of chronic cough
chronic coughsource ↗
▲IND Enabling CompletePreclinical
Indivior completes IND enabling studies for GABAB PAM program in substance use disorders
substance use disorderssource ↗
▲Partnership / LicenseDipraglurantFiledCorporate
Option and collaboration agreement with Sinntaxis for exclusive license to IP covering mGlu5 inhibitors in brain injury recovery
brain injury recoverysource ↗
▼Program DiscontinuationADX71149DiscontinuedCorporate
Termination of development of ADX71149 in epilepsy
epilepsysource ↗
●Partnership / LicenseADX71149DiscontinuedCorporate
Partner returned all development and commercialization rights to ADX71149; partnership terminated
▲Preclinical PoCPreclinical
GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple disease models
chronic coughsource ↗
●IND Enabling CompletePreclinical
Indivior expects to start IND enabling studies for GABAB PAM candidate in H1 2025
substance use disordersource ↗
●IND Enabling CompletePreclinical
Indivior expects to start IND enabling studies for GABAB PAM in substance use disorders
substance use disorderssource ↗
▲Partnership / LicenseDipraglurantFiledCorporate
Entered option and collaboration agreement with Sinntaxis for exclusive license to IP covering mGlu5 NAM in brain injury recovery
brain injury recoverysource ↗
▲Program DiscontinuationADX71149DiscontinuedCorporate
Regained rights to phase 2 mGlu2 PAM asset, ADX71149
▲Oral PresentationPresentation
Presented positive preclinical data for GABAB PAM in chronic cough at American Cough conference
chronic coughsource ↗
●IND Enabling CompletePreclinical
IND enabling studies with GABAB PAM drug candidates from Indivior collaboration expected to start by end of 2024
●IND Enabling CompletePreclinical
Indivior starts IND enabling studies for GABAB PAM candidate
substance use disorderssource ↗
Past FDA Catalysts and PDUFA Decisions
How ADXN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | dipraglurant | Phase 2b/3 topline data readout | Phase 2b/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 83%
Micro Cap(rank 545 of 657)
Percentile Rank
Addex Therapeutics Ltd faces pipeline headwinds (24/100), led by Dipraglurant in Blepharospasm (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dipraglurant Small moleculeCompletedNCT05027997 | Blepharospasm | Phase 2 | COMPLETED | 15 | Nov 27, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADXN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GABAB PAM | chronic cough | 2026-04-21 | significantly reduced cough frequency; similar to baclofen; no signs of tolerance after sub-chronic treatment; superior to nalbuphine, baclofen, codeine or a P2X3 inhibitorRead More | Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough ModelRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADXN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0 % | 305.00 K | 9.00 K | -95% ( -171.00 K) |
ADXN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADXN ranks across every disease it competes in
Competitive Position is a premium feature
See how ADXN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADXN News
ADXNAddex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Addex Therapeutics announced that its spin-out company, Neurosterix, has completed Phase 1 clinical studies of NTX-253, a positive allosteric modulator for schizophrenia. The study provided crucial safety and pharmacokinetic data, supporting the advancement to Phase 2. Addex retains a 20% equity interest in Neurosterix, which raised $65 million in Series A financing.
Read more →ADXNAddex Therapeutics Announces Executive Management Changes
Addex Therapeutics has appointed Jean-Philippe Rocher as the new Head of Pharmaceutical Development, succeeding Mikhail Kalinichev, who is stepping down. Rocher brings over 30 years of experience in drug discovery and development, having previously worked at Addex. His return is expected to significantly contribute to the company's clinical development plans, particularly with several drug candidates ready for trials.
Read more →ADXN▼ -23%on this news
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Addex Therapeutics reported its 2026 Half-Year financial results, highlighting a successful USD 2.8 million fundraising effort. The company regained rights to its GABAB PAM program and noted progress in its spin-out company, Neurosterix, which is advancing in Phase 1 clinical trials. However, financial metrics showed a decrease in net results and cash reserves compared to the previous year.
Read more →ADXN▲ +5.5%on this news· ran to -20% by day 3shared move
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Addex Therapeutics has regained full global rights to its GABAB positive allosteric modulator assets from Indivior. This move follows Indivior's restructuring and merger plans. The regained rights allow Addex to independently advance its GABAB PAM portfolio, which includes candidates for substance use disorders and chronic cough. The company aims to explore new partnerships or further develop these programs.
Read more →ADXNAddex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Addex Therapeutics will report its 2026 Half-Year financial results on September 28, 2026. The CEO and Head of Translational Science will discuss the company's product pipeline during a teleconference. Participants must register in advance to join the call. Addex focuses on developing allosteric modulators for neurological disorders.
Read more →ADXN▲ +8.5%on this news
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Addex Therapeutics has raised USD 2.8 million through its ATM offering, extending its cash runway to the fourth quarter of 2027. The company sold 437,869 ADSs, increasing its outstanding shares to over 210 million. This funding will support the development of its allosteric modulators targeting neurological disorders.
Read more →ADXNAddex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Addex Therapeutics announced the publication of preclinical research on ADX71743, a selective negative allosteric modulator of mGlu7. The study demonstrates its potential in modulating sleep-wake regulation and stress-related neurochemistry in animal models. This research supports the therapeutic potential of mGlu7 in various central nervous system disorders.
Read more →ADXNAddex Shareholders Approve All Resolutions at Annual General Meeting
Addex Therapeutics announced that its shareholders approved all resolutions during the 2026 Annual General Meeting. The approval included the annual report, financial statements for 2025, and compensation reports. Key board members were re-elected, and amendments to the Articles of Association were also approved. The meeting represented 29.35% of the company's outstanding capital.
Read more →ADXNAddex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Addex Therapeutics reported its Q1 2026 financial results, highlighting progress in its spin-out Neurosterix's Phase 1 study of NTX-253 for schizophrenia. The company also advanced its GABAB PAM candidate for chronic cough through preclinical development. Financially, R&D expenses remained low, but cash reserves decreased significantly compared to the previous year.
Read more →ADXN▲ +5.2%on this newsshared move
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Addex Therapeutics will report its First Quarter 2026 Financial Results on June 25, 2026. During a teleconference, CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will discuss the company's product pipeline and provide a business update. The event will be accessible to investors, analysts, and media.
Read more →ADXN▼ -12.5%on this news
Addex Convenes Annual General Meeting 2026
Addex Therapeutics has announced its 2026 Annual General Meeting (AGM) scheduled for June 29, 2026, in Geneva. At the meeting, shareholders will review and approve the annual report and financial statements for 2025, alongside various re-elections of board members and discussions on compensation. The company also plans to address amendments to its Articles of Association during the AGM, signaling ongoing corporate governance and strategic planning.
Read more →ADXNAddex Reports Full Year 2025 Financial Results and Provides Corporate Update
Addex Therapeutics reported its full-year 2025 financial results, highlighting progress in its GABAB PAM chronic cough candidate and the advancement of dipraglurant for brain injury recovery. The company regained rights to its mGlu2 PAM asset, ADX71149, and entered a collaboration with Sinntaxis. Despite a decrease in income and an overall net loss, Addex remains committed to developing innovative treatments for neurological disorders.
Read more →ADXNAddex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Addex Therapeutics announced promising preclinical results for its GABAB PAM candidate, showing significant antitussive activity in a bleomycin-induced chronic cough model. The compound demonstrated reduced cough frequency and improved lung pathology without adverse effects. This positions the candidate as a potential treatment for chronic cough in idiopathic pulmonary fibrosis patients.
Read more →ADXN▼ -7%on this news
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Addex Therapeutics announced that its spin-out company, Neurosterix, is on track to complete a Phase 1 clinical study of NTX-253 for schizophrenia by Q2 2026. The study aims to evaluate the safety, tolerability, and pharmacokinetics of NTX-253, a positive allosteric modulator of the muscarinic M4 receptor. It includes both healthy participants and those with stable schizophrenia, with a focus on generating robust early-stage clinical data.
Read more →ADXNAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Addex Therapeutics announced promising results for its GABAB PAM candidate, showing significant anti-tussive activity in a non-human primate model of chronic cough. The drug candidate reduced cough frequency similarly to baclofen but with fewer side effects. This positions the GABAB PAM as a potential once-daily treatment option for chronic cough patients.
Read more →ADXNAddex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Addex Therapeutics announced the publication of preclinical data in Molecular Psychiatry, highlighting the potential of mGlu7 negative allosteric modulators (NAMs) to transform treatments for anxiety and fear-related disorders. The study showed that ADX71743 can disrupt fear memory reconsolidation, suggesting a novel therapeutic approach. This research may lead to more effective treatments for conditions like PTSD.
Read more →ADXNAddex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Addex Therapeutics announced that its spin-out company Neurosterix has commenced a Phase 1 clinical study for NTX-253, a selective positive allosteric modulator of the M4 receptor intended for schizophrenia treatment. This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy participants. This milestone is significant for both Neurosterix and Addex, as it showcases a novel therapeutic strategy to reduce psychosis symptoms while potentially minimizing traditional antipsychotic side effects.
Read more →ADXN▲ +6.8%on this news
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co. This amendment allows Addex to offer and sell American Depositary Shares (ADSs) for up to $3.3 million at its discretion. The company is not obligated to sell any ADSs, and the agreement includes customary sales commissions and indemnification rights.
Read more →ADXN▼ -6.8%on this news
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Addex Therapeutics reported its Q3 2025 financial results, highlighting significant advancements in its drug candidates, particularly in chronic cough and post-stroke recovery. While the company has made progress in research and development, it also recorded a decline in income and an increase in net losses compared to the previous year. Additionally, the firm observed a decrease in cash reserves over the same period, raising potential concerns about future liquidity. A conference call is scheduled for further discussions on these results.
Read more →ADXN▼ -6.8%on this news
ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of
ADDEX Therapeutics Ltd has released its unaudited interim condensed consolidated financial statements for the nine-month period ending September 30, 2025. The company reported a net loss of 4,891,259 Swiss francs during this period, indicating deterioration compared to prior years. Furthermore, total assets declined significantly by over 3 million Swiss francs, underscoring financial challenges. Operating costs also rose, contributing to a notable operating loss of 2,035,335 Swiss francs.
Read more →About Addex Therapeutics Ltd
HeadquartersGeneva
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next ADXN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime